NASDAQ:AVTX Avalo Therapeutics (AVTX) Stock Price, News & Analysis → Don’t Miss Out on the AI Gold Rush That’s Just Getting Started (From Banyan Hill Publishing) (Ad) Free AVTX Stock Alerts $12.21 +0.58 (+4.99%) (As of 04/22/2024 ET) Add Compare Share Share Today's Range$11.46▼$13.3750-Day Range$4.20▼$21.7552-Week Range$3.95▼$1,130.40Volume83,438 shsAverage Volume560,937 shsMarket Capitalization$12.63 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Avalo Therapeutics alerts: Email Address Avalo Therapeutics MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestBearish7.59% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.64Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.91) to ($0.97) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.28 out of 5 starsMedical Sector884th out of 910 stocksPharmaceutical Preparations Industry412th out of 422 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Avalo Therapeutics. Previous Next 2.0 Short Interest Percentage of Shares Shorted7.59% of the outstanding shares of Avalo Therapeutics have been sold short.Short Interest Ratio / Days to CoverAvalo Therapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Avalo Therapeutics has recently increased by 16.82%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAvalo Therapeutics does not currently pay a dividend.Dividend GrowthAvalo Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AVTX. Previous Next 3.7 News and Social Media Coverage News SentimentAvalo Therapeutics has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.47 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Avalo Therapeutics this week, compared to 1 article on an average week.Search Interest33 people have searched for AVTX on MarketBeat in the last 30 days. This is an increase of 1,000% compared to the previous 30 days.MarketBeat Follows8 people have added Avalo Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 700% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Avalo Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.20% of the stock of Avalo Therapeutics is held by insiders.Percentage Held by Institutions87.06% of the stock of Avalo Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Avalo Therapeutics are expected to decrease in the coming year, from ($0.91) to ($0.97) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Avalo Therapeutics is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Avalo Therapeutics is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAvalo Therapeutics has a P/B Ratio of 1.34. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad DTIA new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… Click here to see me place one of these trades LIVE on camera. About Avalo Therapeutics Stock (NASDAQ:AVTX)Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation. The company's drug candidates include AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as Crohn's disease; Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome; and AVTX-008, a fully human B and T Lymphocyte Attenuator (BTLA) agonist fusion protein. It also develops AVTX-803, a L-fucose monosaccharide therapy for treatment of Leukocyte Adhesion Deficiency Type II. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.Read More AVTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AVTX Stock News HeadlinesApril 17, 2024 | msn.comOppenheimer Upgrades Avalo Therapeutics (AVTX)April 17, 2024 | msn.comAvalo Therapeutics (AVTX) Price Target Increased by 4566.67% to 35.70April 23, 2024 | Wealthpin Pro (Ad)One trade. One ticker. One week. Do you want to target weekly income of up to $2k or more… Starting with just $500... With just one trade per week? April 17, 2024 | americanbankingnews.comAvalo Therapeutics (NASDAQ:AVTX) Upgraded to Outperform at OppenheimerApril 2, 2024 | benzinga.comWhy VirTra Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving PremarketApril 2, 2024 | globenewswire.comAvalo Therapeutics Appoints Biotech Leaders to Board of DirectorsMarch 29, 2024 | marketwatch.comAvalo Therapeutics Shares More than Triple After Co Acquires AlmataBioMarch 29, 2024 | globenewswire.comAvalo Reports 2023 Financial Results and Provides Business UpdatesApril 23, 2024 | Wealthpin Pro (Ad)One trade. One ticker. One week. Do you want to target weekly income of up to $2k or more… Starting with just $500... With just one trade per week? March 29, 2024 | finanznachrichten.deAvalo Therapeutics: Avalo Acquires Anti-IL-1ß mAb and Announces Private Placement Financing of up to $185 MillionMarch 28, 2024 | msn.comMicro-Cap Avalo Therapeutics Stock Rallies As It Snaps AlmataBio For Ex-Eli Lilly Drug For Skin DisorderMarch 28, 2024 | investorplace.comWhy Is Avalo Therapeutics (AVTX) Stock Up 326% Today?March 27, 2024 | globenewswire.comAvalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 MillionFebruary 26, 2024 | finance.yahoo.comAvalo (AVTX) to Report Q4 Earnings: What's in the Cards?January 2, 2024 | benzinga.comAvalo Therapeutics Stock (NASDAQ:AVTX) Dividends: History, Yield and DatesDecember 27, 2023 | msn.comAvalo Therapeutics announces a 1-for-240 reverse stock splitDecember 27, 2023 | finance.yahoo.comAvalo Therapeutics Announces 1-for-240 Reverse Stock SplitDecember 18, 2023 | finance.yahoo.comAvalo Therapeutics, Inc. (AVTX) stock forecast and price targetDecember 7, 2023 | finanznachrichten.deAvalo Therapeutics: Avalo Encourages Stockholders to Vote FOR the Reverse Stock SplitDecember 7, 2023 | finance.yahoo.comAvalo Encourages Stockholders to Vote FOR the Reverse Stock SplitNovember 11, 2023 | benzinga.comAvalo Therapeutics Stock (NASDAQ:AVTX) Earnings Dates and Earning CallsNovember 9, 2023 | morningstar.comAvalo Therapeutics Inc AVTXNovember 9, 2023 | finance.yahoo.comAvalo Therapeutics Inc (AVTX) Announces Q3 2023 Financial Results and Strategic AdvancesNovember 9, 2023 | finance.yahoo.comAvalo Reports Third Quarter 2023 Financial Results and Provides Business UpdatesOctober 31, 2023 | finance.yahoo.comAvalo Completes Divestiture of AVTX-800 SeriesSeptember 27, 2023 | finance.yahoo.comBestGrowthStocks.com Issues a Comprehensive Analysis of Avalo TherapeuticsSeptember 26, 2023 | benzinga.comWhy Avalo Therapeutics Stock Is Up TodaySee More Headlines Receive AVTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Avalo Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/02/2022Today4/22/2024Next Earnings (Estimated)5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:AVTX CUSIPN/A CIK1534120 Webwww.avalotx.com Phone(410) 522-8707FaxN/AEmployees19Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($616.6660) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-31,540,000.00 Net Margins-1,639.50% Pretax Margin-1,638.77% Return on Equity-1,439.87% Return on Assets-113.95% Debt Debt-to-Equity RatioN/A Current Ratio1.82 Quick Ratio1.82 Sales & Book Value Annual Sales$1.92 million Price / Sales6.55 Cash FlowN/A Price / Cash FlowN/A Book Value$9.11 per share Price / Book1.34Miscellaneous Outstanding Shares1,030,000Free Float1,032,000Market Cap$12.58 million OptionableNot Optionable Beta1.13 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Garry A. Neil M.D. (Age 70)Chairman of the Board, President & CEO Comp: $475kMr. Christopher Ryan Sullivan (Age 40)CFO & Head of Investor relations Comp: $350kDr. Solomon H. Snyder M.D. (Age 85)Founder and Chairman of Scientific Advisory Board Dr. Barbara S. Slusher Ph.D. (Age 59)Founder and Member of Scientific Advisory Board Dr. Lisa Hegg Ph.D.Senior Vice President of Program Management, Corporate Infrastructure & Clinical OperationsMs. Colleen MatkowskiSenior Vice President of Global Regulatory Affairs & Quality AssuranceDr. Dino C. Miano Ph.D.Senior Vice President of CMC & Technical OperationsMore ExecutivesKey CompetitorsAytu BioPharmaNASDAQ:AYTUPieris PharmaceuticalsNASDAQ:PIRSNeuroBo PharmaceuticalsNASDAQ:NRBOOrgenesisNASDAQ:ORGSTalpheraNASDAQ:TLPHView All CompetitorsInsidersArmistice Capital, LlcSold 11,442 sharesTotal: $1.68 M ($146.40/share)Caissa Capital Management Ltd.Bought 8 shares on 6/20/2023Total: $7,948.80 ($993.60/share)Caissa Capital Management Ltd.Bought 12 shares on 6/16/2023Total: $11,232.00 ($936.00/share)Caissa Capital Management Ltd.Bought 25 shares on 6/14/2023Total: $20,880.00 ($835.20/share)Caissa Capital Management Ltd.Bought 8 shares on 6/12/2023Total: $8,332.80 ($1,041.60/share)View All Insider Transactions AVTX Stock Analysis - Frequently Asked Questions Should I buy or sell Avalo Therapeutics stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avalo Therapeutics in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" AVTX shares. View AVTX analyst ratings or view top-rated stocks. How have AVTX shares performed in 2024? Avalo Therapeutics' stock was trading at $9.10 at the start of the year. Since then, AVTX stock has increased by 34.2% and is now trading at $12.21. View the best growth stocks for 2024 here. Are investors shorting Avalo Therapeutics? Avalo Therapeutics saw a increase in short interest in March. As of March 31st, there was short interest totaling 78,500 shares, an increase of 16.8% from the March 15th total of 67,200 shares. Based on an average daily trading volume, of 642,100 shares, the days-to-cover ratio is presently 0.1 days. View Avalo Therapeutics' Short Interest. When is Avalo Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our AVTX earnings forecast. How were Avalo Therapeutics' earnings last quarter? Avalo Therapeutics, Inc. (NASDAQ:AVTX) announced its quarterly earnings data on Wednesday, March, 2nd. The company reported ($460.80) EPS for the quarter, missing the consensus estimate of ($432.00) by $28.80. Avalo Therapeutics had a negative net margin of 1,639.50% and a negative trailing twelve-month return on equity of 1,439.87%. When did Avalo Therapeutics' stock split? Avalo Therapeutics shares reverse split on Friday, December 29th 2023. The 1-240 reverse split was announced on Friday, December 29th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, December 29th 2023. An investor that had 100 shares of stock prior to the reverse split would have 0 shares after the split. How do I buy shares of Avalo Therapeutics? Shares of AVTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:AVTX) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingThe A.I. story nobody is telling you (Read ASAP)TradeSmithHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportDid You Get Your Free Bitcoin Yet?Crypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders Agency[Shocking] Elon Musk’s Plan To End BanksCrypto 101 MediaUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avalo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
